# Fecal Colonization with Extended-Spectrum Beta-Lactamase and AmpC-ProducingEscherichia coli

Authors: Mohamed H. Al-Agamy; Taghrid S. El Mahdy; Atef M. Shibl
Journal: BioMed Research International
 (2016)

---

## Abstract

Background. Extended-spectrum β-lactamases (ESβLs) and AmpC β-lactamases cause β-lactam resistance inEscherichia coli. Fecal colonization by ESβL- and/or AmpC-positiveE. coli is a source of nosocomial infections.Methods. In order to investigate inpatient fecal colonization by ESβLs and AmpC, antibiotic sensitivity tests were conducted and minimum inhibitory concentrations (MICs) were determined using the disk diffusion method andE-test, respectively. Characterization of ESβL and AmpC was performed usingE-test strips, and a set of PCRs and DNA sequence analyses were used to characterize the ESβL and AmpC genes.Results. The whole collection ofE. coli isolates (n
=
50) was sensitive to imipenem, tigecycline, colistin, and fosfomycin, while 26% of the isolates showed reduced susceptibility to ceftazidime (MIC ≥ 4 μg/mL). ESβL was phenotypically identified in 26% (13/50) of cases, while AmpC activity was detected in two ESβL-producingE. coli isolates. All ESβL-producingE. coli were positive for the CTX-M gene, eleven isolates carried b
l
a
CTX-M-15, and two isolates carried b
l
a
CTX-M-14 gene. Two CTX-M-positiveE. coli isolates carried b
l
a
CMY-2.Conclusions. The alimentary tract is a significant reservoir for ESβL- and/or AmpC-producingE. coli, which may lead to nosocomial infection.


---

## Body

## 1. Introduction

A remarkable increase in fecal colonization rates with extended-spectrum beta-lactamase- (ESβL-), AmpC-plasmid mediated-, and/or carbapenemases-producing Enterobacteriaceae has been reported in many regions worldwide [1, 2]. Infections caused by Enterobacteriaceae, which are resistant to β-lactams, are coupled with the inappropriate use of antibiotics and/or a prolonged period of hospital admission. The rising use of carbapenems for empirical treatment of nosocomial infections has led to fast global dissemination of carbapenemase-positiveenterobacterial strains [3]. ESβLs arise through point mutations in TEM-1/TEM-2 and SHV-1. However, over the last three decades, non-TEM and non-SHV ESβLs strains have been detected, primarily CTX-M. Enterobacteriaceae that produce CTX-M enzymes have shown rapid and concerning dissemination and have been documented as the most prevalent etiological infectious agents [4]. ESβL confers resistance to penicillins, cephalosporins, and monobactam (aztreonam), but they are susceptible to cephamycins (cefoxitin and cefotetan) and carbapenems (imipenem, meropenem, and doripenem) and are typically reserved by inhibitors of Ambler class A β-lactamase (clavulanic acid, tazobactam, or sulbactam). Most ESβLs can hydrolyze fourth-generation cephalosporins. While AmpC β-lactamases confer resistance to penicillins, third-generation cephalosporins, monobactam, and cephamycins, they are sensitive to carbapenem and are not inhibited by β-lactamase inhibitors; however, they are inhibited by cloxacillin [5–7].Numerous studies in Saudi Arabia have focused on the identification of ESβL-producing strains from clinical specimens [4], but there are few reports on the fecal colonization of ESβL-producing isolates in Saudi Arabia. Therefore, in the present study, we determine the incidence of ESβL- and/or AmpC cephalosporinase-producingEscherichia coli isolates in human fecal flora and investigated the genes encoding the corresponding enzymes.


## 2. Materials and Methods

### 2.1. Bacterial Identification

Fifty differentE. coli isolates were isolated from 50 stool samples of different inpatients carriers, under nonoutbreak conditions, at a hospital in Riyadh, Saudi Arabia, from April 2014 to June 2014. Briefly, fresh stool specimens were aseptically collected and transported to the microbiology laboratory. Stool samples were suspended in sterile phosphate-buffered saline, pH 7. A 100 μL volume was directly inoculated onto blood agar and Eosin Methylene Blue agar (Oxoid Microbiology Products, Hampshire, UK). After 48 h incubation at 37°C, the isolated organisms were identified by conventional procedures and automated identification systems with the API20E identification kit (bioMerieux, Marcy l’Etoile, France). These isolates were preserved in brain heart infusion broth containing 20% glycerol at −70°C.


### 2.2. Phenotypic Detection of ESβL

The isolates showing reduced susceptibility to ceftazidime (CAZ), cefotaxime (CTX), or aztreonam (ATM) (minimum inhibitory concentration (MIC) ≥ 1μg/mL or zone diameter ≤ 22 mm) were selected for screening of ESβL production (Clinical and Laboratory Standards Institute (CLSI), 2014).E-test ESβL strips were used in accordance with the manufacturer’s instructions to evaluate ESβL production. The CAZ/ceftazidime + clavulanate- (CAZ/CAL-) ESβLE-test strip was used to detect ESβL production. The test is considered positive if the ratio of MIC of CAZ/CAL is ≥8. To inhibit AmpC β-lactamase, the CAZ/CAL-ESβLE-test was carried out on cloxacillin Mueller-Hinton agar, and the results were interpreted in a similar manner.


### 2.3. Phenotypic Detection of AmpC

The isolates showing reduced susceptibility to cefoxitin (FOX) or cefotetan (CTT) (zone diameter of 18 or 16 mm, resp.) were selected for screening of AmpC enzyme production [9]. The phenotypic detection test consists of a strip containing CTT on one end and CTT-cloxacillin (CTT/CXT) on the other end. Ratios of the MICs of CTT/CXT ≥ 8 are considered to indicate positive AmpC β-lactamase production.


### 2.4. Susceptibility Testing

MICs for the isolates showing a phenotype of producing ESβL and AmpC activities were determined by usingE-test strips (bioMerieux, Marcy l’Etoile, France). Interpretation was based on the Clinical and Laboratory Standards Institute (CLSI) criteria [9].Escherichia coli ATCC 25922 strains were used as reference strains. The following antibiotics were tested: piperacillin (PIP), piperacillin/tazobactam (TZP), CAZ, CAZ/CAL, CTX, cefepime (FEP), ATM, FOX, CTT, CTT/CXT, imipenem (IMI), gentamicin (GM), amikacin (AK), ciprofloxacin (CI), colistin (COL), tigecycline (TGC), and fosfomycin (FOS).


### 2.5. Screening for the Presence ofβ-Lactamase Genes

The isolate was cultured in 2 mL of Tryptic Soy Broth (Difco, Franklin Lakes, NJ, USA). A 200μL volume of overnight culture was heated at 99°C in a heat block for 10 min. The obtained DNA was used in polymerase chain reaction (PCR) assays on a Techne Flexigene Thermal Cycler (Techne, Duxford, Cambridge, UK). Positive and negative controls were included in all PCR assays. All PCR products were analyzed on 0.8% agarose gels (incorporated with 0.5 mg/L ethidium bromide) and then visualized under UV light (Pharmacia LKB, Biotechnology AB, Gothenburg, Sweden) and photographed using a documentation system (CE, DP-CF-011.C, European Union).The PCR primers used are listed in Table1. The primers were used to search for class A β-lactamase genes (b
l
a
TEM, b
l
a
SHV, b
l
a
OXA-1, and b
l
a
CTX-M families) and class C β-lactamase genes (b
l
a
CMY, b
l
a
MOX, b
l
a
FOX, b
l
a
DHA, b
l
a
ACC, b
l
a
ACT, b
l
a
MIR, b
l
a
EBC, b
l
a
CIT, and b
l
a
BIL). PCR assays were conducted as previously described [8].Table 1
Primers used for amplification of the testedβ-lactamase genes (Dallenne et al., 2010 [8]).
PCR type
Target
Primer
Sequence of primers (5′-3′)
Amplified products (bp)
Multiplex I TEM, SHV, and OXA-1-like
TEM
MultiTSO-T_for
CATTTCCGTGTCGCCCTTATTC
800
MultiTSO-T_rev
CGTTCATCCATAGTTGCCTGAC
SHV
MultiTSO-S_for
AGCCGCTTGAGCAAATTAAAC
713
MultiTSO-S_rev
ATCCCGCAGATAAATCACCAC
OXA-1
MultiTSO-O_for
GGCACCAGATTCAACTTTCAAG
564
MultiTSO-O_rev
GACCCCAAGTTTCCTGTAAGTG
Multiplex II CTX-M group 1, group 2, and group 9
CTX-M group 1
MultiCTXMGp1_for
TTAGGAARTGTGCCGCTGYA
688
MultiCTXMGp1-2_rev
CGATATCGTTGGTGGTRCCAT
CTX-M group 2
MultiCTXMGp2_for
CGTTAACGGCACGATGAC
404
MultiCTXMGp1-2_rev
CGATATCGTTGGTGGTRCCAT
CTX-M group 9
MultiCTXMGp9_for
TCAAGCCTGCCGATCTGGT
561
MultiCTXMGp9_rev
TGATTCTCGCCGCTGAAG
CTX-M group 8/25
CTX-M group 8/25
CTX-Mg8/25_for
AACRCRCAGACGCTCTAC
326
CTX-Mg8/25_rev
TCGAGCCGGAASGTGTYAT
Multiplex III ACC, FOX, MOX, DHA, CIT, and EBC
ACC-1 and ACC-2
MultiCaseACC_for
CACCTCCAGCGACTTGTTAC
346
MultiCaseACC_rev
GTTAGCCAGCATCACGATCC
FOX-1 to FOX-5
MultiCaseFOX_for
CTACAGTGCGGGTGGTTT
162
MultiCaseFOX_rev
CTATTTGCGGCCAGGTGA
MOX-1, MOX-2, CMY-1, CMY-8 to CMY-11, and CMY-19
MultiCaseMOX_for
GCAACAACGACAATCCATCCT
895
MultiCaseMOX_rev
GGGATAGGCGTAACTCTCCCAA
DHA-1 and DHA-2
MultiCaseDHA_for
TGATGGCACAGCAGGATATTC
997
MultiCaseDHA_rev
GCTTTGACTCTTTCGGTATTCG
LAT-1 to LAT-3, BIL-1, CMY-2 to CMY-7, CMY-12 to CMY-18, and CMY-21 to CMY-23
MultiCaseCIT_for
CGAAGAGGCAATGACCAGAC
538
MultiCaseCIT_rev
ACGGACAGGGTTAGGATAGY
ACT-1 and MIR-1
MultiCaseEBC_for
CGGTAAAGCCGATGTTGCG
683


### 2.6. Sequencing ofβ-Lactamase Genes

Purification of PCR amplicons was performed using a PCR purification kit (Qiagen, Hilden, Germany). PCR products ofbla genes were sequenced on both strands using PCR primers to determine their molecular types. DNA sequences were analyzed using the ABI 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s recommendations.


## 2.1. Bacterial Identification

Fifty differentE. coli isolates were isolated from 50 stool samples of different inpatients carriers, under nonoutbreak conditions, at a hospital in Riyadh, Saudi Arabia, from April 2014 to June 2014. Briefly, fresh stool specimens were aseptically collected and transported to the microbiology laboratory. Stool samples were suspended in sterile phosphate-buffered saline, pH 7. A 100 μL volume was directly inoculated onto blood agar and Eosin Methylene Blue agar (Oxoid Microbiology Products, Hampshire, UK). After 48 h incubation at 37°C, the isolated organisms were identified by conventional procedures and automated identification systems with the API20E identification kit (bioMerieux, Marcy l’Etoile, France). These isolates were preserved in brain heart infusion broth containing 20% glycerol at −70°C.


## 2.2. Phenotypic Detection of ESβL

The isolates showing reduced susceptibility to ceftazidime (CAZ), cefotaxime (CTX), or aztreonam (ATM) (minimum inhibitory concentration (MIC) ≥ 1μg/mL or zone diameter ≤ 22 mm) were selected for screening of ESβL production (Clinical and Laboratory Standards Institute (CLSI), 2014).E-test ESβL strips were used in accordance with the manufacturer’s instructions to evaluate ESβL production. The CAZ/ceftazidime + clavulanate- (CAZ/CAL-) ESβLE-test strip was used to detect ESβL production. The test is considered positive if the ratio of MIC of CAZ/CAL is ≥8. To inhibit AmpC β-lactamase, the CAZ/CAL-ESβLE-test was carried out on cloxacillin Mueller-Hinton agar, and the results were interpreted in a similar manner.


## 2.3. Phenotypic Detection of AmpC

The isolates showing reduced susceptibility to cefoxitin (FOX) or cefotetan (CTT) (zone diameter of 18 or 16 mm, resp.) were selected for screening of AmpC enzyme production [9]. The phenotypic detection test consists of a strip containing CTT on one end and CTT-cloxacillin (CTT/CXT) on the other end. Ratios of the MICs of CTT/CXT ≥ 8 are considered to indicate positive AmpC β-lactamase production.


## 2.4. Susceptibility Testing

MICs for the isolates showing a phenotype of producing ESβL and AmpC activities were determined by usingE-test strips (bioMerieux, Marcy l’Etoile, France). Interpretation was based on the Clinical and Laboratory Standards Institute (CLSI) criteria [9].Escherichia coli ATCC 25922 strains were used as reference strains. The following antibiotics were tested: piperacillin (PIP), piperacillin/tazobactam (TZP), CAZ, CAZ/CAL, CTX, cefepime (FEP), ATM, FOX, CTT, CTT/CXT, imipenem (IMI), gentamicin (GM), amikacin (AK), ciprofloxacin (CI), colistin (COL), tigecycline (TGC), and fosfomycin (FOS).


## 2.5. Screening for the Presence ofβ-Lactamase Genes

The isolate was cultured in 2 mL of Tryptic Soy Broth (Difco, Franklin Lakes, NJ, USA). A 200μL volume of overnight culture was heated at 99°C in a heat block for 10 min. The obtained DNA was used in polymerase chain reaction (PCR) assays on a Techne Flexigene Thermal Cycler (Techne, Duxford, Cambridge, UK). Positive and negative controls were included in all PCR assays. All PCR products were analyzed on 0.8% agarose gels (incorporated with 0.5 mg/L ethidium bromide) and then visualized under UV light (Pharmacia LKB, Biotechnology AB, Gothenburg, Sweden) and photographed using a documentation system (CE, DP-CF-011.C, European Union).The PCR primers used are listed in Table1. The primers were used to search for class A β-lactamase genes (b
l
a
TEM, b
l
a
SHV, b
l
a
OXA-1, and b
l
a
CTX-M families) and class C β-lactamase genes (b
l
a
CMY, b
l
a
MOX, b
l
a
FOX, b
l
a
DHA, b
l
a
ACC, b
l
a
ACT, b
l
a
MIR, b
l
a
EBC, b
l
a
CIT, and b
l
a
BIL). PCR assays were conducted as previously described [8].Table 1
Primers used for amplification of the testedβ-lactamase genes (Dallenne et al., 2010 [8]).
PCR type
Target
Primer
Sequence of primers (5′-3′)
Amplified products (bp)
Multiplex I TEM, SHV, and OXA-1-like
TEM
MultiTSO-T_for
CATTTCCGTGTCGCCCTTATTC
800
MultiTSO-T_rev
CGTTCATCCATAGTTGCCTGAC
SHV
MultiTSO-S_for
AGCCGCTTGAGCAAATTAAAC
713
MultiTSO-S_rev
ATCCCGCAGATAAATCACCAC
OXA-1
MultiTSO-O_for
GGCACCAGATTCAACTTTCAAG
564
MultiTSO-O_rev
GACCCCAAGTTTCCTGTAAGTG
Multiplex II CTX-M group 1, group 2, and group 9
CTX-M group 1
MultiCTXMGp1_for
TTAGGAARTGTGCCGCTGYA
688
MultiCTXMGp1-2_rev
CGATATCGTTGGTGGTRCCAT
CTX-M group 2
MultiCTXMGp2_for
CGTTAACGGCACGATGAC
404
MultiCTXMGp1-2_rev
CGATATCGTTGGTGGTRCCAT
CTX-M group 9
MultiCTXMGp9_for
TCAAGCCTGCCGATCTGGT
561
MultiCTXMGp9_rev
TGATTCTCGCCGCTGAAG
CTX-M group 8/25
CTX-M group 8/25
CTX-Mg8/25_for
AACRCRCAGACGCTCTAC
326
CTX-Mg8/25_rev
TCGAGCCGGAASGTGTYAT
Multiplex III ACC, FOX, MOX, DHA, CIT, and EBC
ACC-1 and ACC-2
MultiCaseACC_for
CACCTCCAGCGACTTGTTAC
346
MultiCaseACC_rev
GTTAGCCAGCATCACGATCC
FOX-1 to FOX-5
MultiCaseFOX_for
CTACAGTGCGGGTGGTTT
162
MultiCaseFOX_rev
CTATTTGCGGCCAGGTGA
MOX-1, MOX-2, CMY-1, CMY-8 to CMY-11, and CMY-19
MultiCaseMOX_for
GCAACAACGACAATCCATCCT
895
MultiCaseMOX_rev
GGGATAGGCGTAACTCTCCCAA
DHA-1 and DHA-2
MultiCaseDHA_for
TGATGGCACAGCAGGATATTC
997
MultiCaseDHA_rev
GCTTTGACTCTTTCGGTATTCG
LAT-1 to LAT-3, BIL-1, CMY-2 to CMY-7, CMY-12 to CMY-18, and CMY-21 to CMY-23
MultiCaseCIT_for
CGAAGAGGCAATGACCAGAC
538
MultiCaseCIT_rev
ACGGACAGGGTTAGGATAGY
ACT-1 and MIR-1
MultiCaseEBC_for
CGGTAAAGCCGATGTTGCG
683


## 2.6. Sequencing ofβ-Lactamase Genes

Purification of PCR amplicons was performed using a PCR purification kit (Qiagen, Hilden, Germany). PCR products ofbla genes were sequenced on both strands using PCR primers to determine their molecular types. DNA sequences were analyzed using the ABI 3100 Genetic Analyzer (Applied Biosystems, Foster City, CA, USA) according to the manufacturer’s recommendations.


## 3. Results

### 3.1. Bacterial Identification

Fifty fecalE. coli samples were isolated randomly from hospitalized patients in Riyadh, Saudi Arabia. The patients were treated for noninfectious diseases under nonoutbreak conditions.Escherichia coli isolates were identified manually and according to the API20E identification kit (bioMerieux, Marcy l’Etoile, France).


### 3.2. Characterization ofb
l
a
ES
β
L and b
l
a
AmpC

Thirteen of the 50E. coli isolates, which showed reduced susceptibility to CAZ, CTX, or ATM (MIC ≥ 1 μg/mL or inhibition zone ≤ 22 mm), were selected for screening of ESβL and AmpC enzyme production using CAZ/CAL-ESβL and CTT/CXT-AmpCE-test strips. Thirteen isolates were positive for ESβL and two ESβL-positive isolates produced AmpC β-lactamase.PCR was used to detectb
l
a
ES
β
L genes andAmpC plasmid-mediated genes in ESβL- and AmpC-positiveE. coli isolates (n
=
13). The results of PCR and DNA sequencing ofbla genes are shown in Table 2.Table 2
Antimicrobial susceptibility profiles of ESβL- and AmpC-producing E. coli isolates from fecal samples and associated resistance patterns.
Isolates number
E-test MIC (mg/L)
Resistance genes
PIP
TZP
CTX
CAZ
CAZ/CAL
FEP
ATM
FOX
CTT
CTT/CXT
IMI
GM
AK
CI
COL
TGC
FOS
EC1
>256
<1
>256
32
32/2
4
8
0.032
0.25
<0.5/<0.5
0.06
0.5
2
1
<0.016
0.25
0.016
TEM-1+CTX-M-15+OXA-1
EC2
>256
<1
>256
16
16/0.5
4
16
0.065
0.25
<0.5/<0.5
0.12
1.5
3
0.25
<0.016
0.25
<0.016
TEM-1+CTX-M-15++SHV-1
EC3
>256
64
>256
>256
>32/4
12
>256
0.125
0.25
<0.5/<0.5
0.25
64
3
4
<0.016
0.125
<0.016
TEM-1+CTX-M-15+OXA-1
EC4
>256
8
>256
32
32/0.064
8
16
0.032
0.06
<0.5/<0.5
0.06
12
4
4
<0.016
0.125
<0.016
TEM-1+CTX-M-15+OXA-1
EC5
>256
32
>256
16
16/0.5
4
12
0.125
0.125
<0.5/<0.5
0.03
8
3
6
<0.016
0.25
<0.016
TEM-1+CTX-M-15+SHV-1
EC6
>256
8
>256
>256
>32/4
192
>256
0.25
0.25
<0.5/<0.5
0.06
192
48
>32
<0.016
0.25
<0.016
TEM-1+CTX-M-15+OXA-1
EC7
>256
8
>256
>256
>32/4
128
192
0.25
0.25
<0.5/<0.5
0.12
128
16
>32
<0.016
0.25
<0.016
TEM-1+CTX-M-15+OXA-1
EC8
>256
<1
>256
>256
>32/4
96
128
0.25
0.25
<0.5/<0.5
0.06
96
0.5
0.25
<0.016
0.25
0.125
TEM-1+CTX-M-14+OXA-1
EC9
>256
16
>256
4
4/0.064
3
3
0.032
0.032
<0.5/<0.5
0.06
8
2
0.25
<0.016
0.38
<0.016
TEM-1+CTX-M-15
EC10
>256
4
>256
6
6/0.125
4
6
0.032
0.032
<0.5/<0.5
0.125
16
1
0.5
<0.016
0.25
<0.016
TEM-1+CTX-M-15+SHV-1
EC11
>256
<1
>256
48
>32/1
8
24
0.032
0.032
<0.5/<0.5
0.25
2
32
1
<0.016
0.25
<0.016
TEM-1+CTX-M-14+OXA-1
EC12
>256
>256
>256
>256
>32/>4
48
>256
64
32
32/32
0.25
>256
192
0.75
<0.016
0.25
0.016
TEM-1+CTX-M-15+CMY-2+OXA-1
EC13
>256
128
>256
>256
>32/>4
64
>256
64
48
>32/>32
0.25
128
4
>32
<0.016
0.38
0.016
TEM-1+CTX-M-15+CMY-2
PIP: piperacillin; TZP: piperacillin/tazobactam; CAZ: ceftazidime; CAZ/CAL: ceftazidime/ceftazidime + clavulanic acid; CTX: cefotaxime; FEP: cefepime; ATM: aztreonam; FOX: cefoxitin; CTT: cefotetan; CTT/CXT: cefotetan/cefotetan + cloxacillin; IMI: imipenem; GM: gentamicin; AK: amikacin; CI: ciprofloxacin; COL: colistin; TGC: tigecycline; FOS: fosfomycin.Eleven of 13 ESβL-producingE. coli isolates were found to contain CTX-M-15, while two isolates harbored b
l
a
CTX-M-14. CMY-2-positive isolates (n
=
2) were concomitant with CTX-M-15. All ESβL-producingE. coli isolates (n
=
13) were positive for b
l
a
TEM-1, while eight (61.5%) isolates carried b
l
a
OXA-1. In contrast, three (23%) isolates were found to contain b
l
a
SHV-1.


### 3.3. Antimicrobial Resistance Pattern of ESβL and AmpC Enzyme-Positive Isolates

The MICs of 17 antimicrobial agents were determined forE. coli fecal isolates. The results of the susceptibility pattern for ESβL and AmpC enzyme-producingE. coli isolates are illustrated in Table 2.


## 3.1. Bacterial Identification

Fifty fecalE. coli samples were isolated randomly from hospitalized patients in Riyadh, Saudi Arabia. The patients were treated for noninfectious diseases under nonoutbreak conditions.Escherichia coli isolates were identified manually and according to the API20E identification kit (bioMerieux, Marcy l’Etoile, France).


## 3.2. Characterization ofb
l
a
ES
β
L and b
l
a
AmpC

Thirteen of the 50E. coli isolates, which showed reduced susceptibility to CAZ, CTX, or ATM (MIC ≥ 1 μg/mL or inhibition zone ≤ 22 mm), were selected for screening of ESβL and AmpC enzyme production using CAZ/CAL-ESβL and CTT/CXT-AmpCE-test strips. Thirteen isolates were positive for ESβL and two ESβL-positive isolates produced AmpC β-lactamase.PCR was used to detectb
l
a
ES
β
L genes andAmpC plasmid-mediated genes in ESβL- and AmpC-positiveE. coli isolates (n
=
13). The results of PCR and DNA sequencing ofbla genes are shown in Table 2.Table 2
Antimicrobial susceptibility profiles of ESβL- and AmpC-producing E. coli isolates from fecal samples and associated resistance patterns.
Isolates number
E-test MIC (mg/L)
Resistance genes
PIP
TZP
CTX
CAZ
CAZ/CAL
FEP
ATM
FOX
CTT
CTT/CXT
IMI
GM
AK
CI
COL
TGC
FOS
EC1
>256
<1
>256
32
32/2
4
8
0.032
0.25
<0.5/<0.5
0.06
0.5
2
1
<0.016
0.25
0.016
TEM-1+CTX-M-15+OXA-1
EC2
>256
<1
>256
16
16/0.5
4
16
0.065
0.25
<0.5/<0.5
0.12
1.5
3
0.25
<0.016
0.25
<0.016
TEM-1+CTX-M-15++SHV-1
EC3
>256
64
>256
>256
>32/4
12
>256
0.125
0.25
<0.5/<0.5
0.25
64
3
4
<0.016
0.125
<0.016
TEM-1+CTX-M-15+OXA-1
EC4
>256
8
>256
32
32/0.064
8
16
0.032
0.06
<0.5/<0.5
0.06
12
4
4
<0.016
0.125
<0.016
TEM-1+CTX-M-15+OXA-1
EC5
>256
32
>256
16
16/0.5
4
12
0.125
0.125
<0.5/<0.5
0.03
8
3
6
<0.016
0.25
<0.016
TEM-1+CTX-M-15+SHV-1
EC6
>256
8
>256
>256
>32/4
192
>256
0.25
0.25
<0.5/<0.5
0.06
192
48
>32
<0.016
0.25
<0.016
TEM-1+CTX-M-15+OXA-1
EC7
>256
8
>256
>256
>32/4
128
192
0.25
0.25
<0.5/<0.5
0.12
128
16
>32
<0.016
0.25
<0.016
TEM-1+CTX-M-15+OXA-1
EC8
>256
<1
>256
>256
>32/4
96
128
0.25
0.25
<0.5/<0.5
0.06
96
0.5
0.25
<0.016
0.25
0.125
TEM-1+CTX-M-14+OXA-1
EC9
>256
16
>256
4
4/0.064
3
3
0.032
0.032
<0.5/<0.5
0.06
8
2
0.25
<0.016
0.38
<0.016
TEM-1+CTX-M-15
EC10
>256
4
>256
6
6/0.125
4
6
0.032
0.032
<0.5/<0.5
0.125
16
1
0.5
<0.016
0.25
<0.016
TEM-1+CTX-M-15+SHV-1
EC11
>256
<1
>256
48
>32/1
8
24
0.032
0.032
<0.5/<0.5
0.25
2
32
1
<0.016
0.25
<0.016
TEM-1+CTX-M-14+OXA-1
EC12
>256
>256
>256
>256
>32/>4
48
>256
64
32
32/32
0.25
>256
192
0.75
<0.016
0.25
0.016
TEM-1+CTX-M-15+CMY-2+OXA-1
EC13
>256
128
>256
>256
>32/>4
64
>256
64
48
>32/>32
0.25
128
4
>32
<0.016
0.38
0.016
TEM-1+CTX-M-15+CMY-2
PIP: piperacillin; TZP: piperacillin/tazobactam; CAZ: ceftazidime; CAZ/CAL: ceftazidime/ceftazidime + clavulanic acid; CTX: cefotaxime; FEP: cefepime; ATM: aztreonam; FOX: cefoxitin; CTT: cefotetan; CTT/CXT: cefotetan/cefotetan + cloxacillin; IMI: imipenem; GM: gentamicin; AK: amikacin; CI: ciprofloxacin; COL: colistin; TGC: tigecycline; FOS: fosfomycin.Eleven of 13 ESβL-producingE. coli isolates were found to contain CTX-M-15, while two isolates harbored b
l
a
CTX-M-14. CMY-2-positive isolates (n
=
2) were concomitant with CTX-M-15. All ESβL-producingE. coli isolates (n
=
13) were positive for b
l
a
TEM-1, while eight (61.5%) isolates carried b
l
a
OXA-1. In contrast, three (23%) isolates were found to contain b
l
a
SHV-1.


## 3.3. Antimicrobial Resistance Pattern of ESβL and AmpC Enzyme-Positive Isolates

The MICs of 17 antimicrobial agents were determined forE. coli fecal isolates. The results of the susceptibility pattern for ESβL and AmpC enzyme-producingE. coli isolates are illustrated in Table 2.


## 4. Discussion

The human and animal alimentary tracts are vital reservoirs for ESβL-, carbapenemases-, and AmpC enzyme-producing Enterobacteriaceae. Patient-to-patient transmission of resistant microorganisms may occur in hospitals [10, 11]. The overuse of antibiotics has recently been associated with the emergence of resistant intestinal bacteria, particularly ESβL-, carbapenemases-, and AmpC enzyme-producing Enterobacteriaceae. Numerous studies have demonstrated that exposure to β-lactam antibiotics is a risk factor for the selection of multidrug-resistantE. coli [12]. Therefore, the current study examined the antimicrobial resistance patterns of fecalE. coli isolates, as well as the molecular basis for their β-lactam resistance mechanisms, using phenotypic and genotypic methods. The present study included 50 patients admitted to a hospital in Riyadh, Saudi Arabia, from April 2014 to June 2014. These patients were treated for noninfectious diseases under nonoutbreak conditions. Fifty fecal stool specimens collected from the 50 patients were cultured on blood agar and EMB agar as described in Materials and Methods. Fifty suspectedE. coli isolates were selected and the isolates were identified by conventional procedures and using the API20E identification kit. All isolates were identified asE. coli.Production ofβ-lactamases is the main mechanism of β-lactam resistance in Gram-negative bacteria, includingE. coli [6, 7]. Several β-lactamases (ESβLs, AmpC enzymes, and carbapenemases) have been previously reported in fecalE. coli isolates [13–15].In the present study, 100% of 50E. coli isolates were found to be sensitive to imipenem and 13 (26%) of 50 isolates were resistant or showed reduced susceptibility to CAZ, CTX-M, or ATM. The carbapenem susceptibility results indicated that our isolates did not harbor carbapenemase, while 26% (13/50) of theE. coli isolates harbored ESβL and/or AmpC β-lactamase. Two of 13 isolates exhibited reduced susceptibility to cephamycins (FOX and CTT).Phenotypic screening for the presence of different types ofβ-lactamases was conducted usingE. coli isolates. ThirteenE. coli isolates were selected for screening of ESβL and AmpC β-lactamase production using CAZ/CAL-ESβL, and CTT/CXT-AmpCE-test strips were used to detect ESβL production. Using phenotypic detection methods, all isolates were found to produce ESβL, while two isolates phenotypically produced AmpC enzyme. A battery of PCR assays was conducted to detect b
l
a
ES
β
L genes and AmpC plasmid-mediated genes in the 13E. coli isolates. Therefore, class A and class C β-lactamase genes were tested. The PCR-purified product was subjected to DNA sequencing to identify the gene variants. The results of molecular characterization ofbla genes are shown in Table 2. PCR amplification and DNA sequencing analyses of the PCR products showed that all isolates possessed a CTX-M-type ESβL and that b
l
a
CTX-M-15 was present in 1 isolate, while two isolates contained b
l
a
CTX-M-14. Other CTX-M families were not detected. The gene encoding CMY-2 enzyme was detected in twoE. coli isolates. CMY-2-positive isolates are concomitant with CTX-M-15. AllE. coli isolates (n
=
13) were positive for b
l
a
TEM-1, while 61.5% and 23% of the isolates contained b
l
a
OXA-1 and b
l
a
SHV-1, respectively. The increase in expression of the AmpC β-lactamases may mask the recognition of ESβLs [16]. Therefore, in the present study, the genotypic methods revealed that all 13 strains were ESβL CTX-M-positive, while phenotypic methods showed that 11 strains were ESβL-positive and two strains were AmpC enzyme-positive. AmpC-producing strains producing CTX-M-15 may act as a dormant reservoir for ESβLs.Numerous studies have documented a remarkable increase in intestinal colonization rates with ESβL- and AmpC enzyme-producing Enterobacteriaceae in many countries [2, 10, 11, 14–17]. The prevalence of ESβL-producingE. coli fecal isolates varies widely from country to country, from region to region, and at different time periods. A high incidence of fecal carriage rate of ESβL-producingE. coli has been observed in Asia, Africa, and South America [13, 14, 18–21], while a significantly lower prevalence of ESβL-producingE. coli fecal isolates was reported in most European countries [22, 23]. In Argentina, the rate of fecal carriage of Enterobacteriaceae-resistant strains to third-generation cephalosporins was 26.8% [20]. Villar et al. [20] reported that 20.22% and 6.7% of fecal strains were colonized by ESβL- and AmpC enzyme-producing Enterobacteriaceae [20]. In Egypt, Al-Agamy et al. reported that 22.6% and 3.22% of hospitalized patients were colonized by ESβL- and AmpC-positiveE. coli, respectively. The b
l
a
CTX-M-like gene was the predominant ESβL gene, detected in 71.4% of ESβL-producingE. coli isolates [21]. In a recent study in Egypt, Bassyouni et al. reported that 21% and 3% of patients were colonized by ESβL- and AmpC-producingE. coli, respectively. They also found that b
l
a
SHV gene was the predominant ESβL gene, detected in 81.8% of the resistantE. coli isolates [13]. In Korea, 20.3% of fecal Enterobacteriaceae members were ESβLs [19]. In India, the prevalence of ESβL-positiveE. coli isolates was 19% in healthy volunteers from the community [14]. In Libya, 13.4% and 6.7% ofE. coli isolates were ESβLs- and AmpC-positive, respectively [18]. In a previous study in Saudi Arabia, 17.7% of strains were found to be ESβL-positive [24]. A high (26.1%) prevalence was detected in inpatients, followed by outpatients (15.4%), and the lowest prevalence rate (13.1%) was detected in healthy individuals [24]. In the present study, the prevalence of ESβL-producingE. coli was 26%. Despite differences in the date and region of isolation, the prevalence of fecal carriage rate of ESβL in the present study (26%) was in agreement with the prevalence (26.1%) reported by Kader et al. In contrast, the prevalence rate of ESβL-producing Enterobacteriaceae was 2.9% among healthy Swedish children.Escherichia coli containing CTX-M β-lactamase predominated, and only oneE. coli isolate harbored genes encoding for CMY [22]. The carriage rate of ESβL- and AmpC enzyme-producingE. coli was 3.57% and 2.38% among 84 Danish army recruits, respectively. b
l
a
CTX-M-14 gene was the predominant ESβL gene detected in three (100%) ESβL-producingE. coli isolates, while b
l
a
CMY-2 was detected in two AmpC enzyme-producingE. coli isolates [23]. In Spain, the prevalence of ESβL and AmpC enzyme carriers was 5.06% and 0.59%, respectively [25]. b
l
a
CTX-M genes were the ESβL dominating genes (96.15%) and CTX-M-14 was the most prevalent gene (50%), followed by CTX-M-15 (40%). CMY-2 was the most prevalent gene (81.25%), followed by DHA-1 (18.75%) [25].MICs were determined for ESβL- and AmpC enzyme-producingE. coli (n
=
13) isolates. The results of MIC are shown in Table 2.In conclusion, a high incidence of carriage of ESβL-positiveE. coli fecal isolates among hospitalized patients in Riyadh was detected, reaching 26%, with b
l
a
CTX-M-15 (84.6%) being the most predominant gene. The emergence of fecal carriage of CMY-2-producingE. coli among hospitalized patients has been reported to be 4%. These outcomes emphasize the importance of the intestinal tract as a reservoir for ESβL- and AmpC enzyme-producingE. coli, which may lead to nosocomial infection. The admission of colonized fecal carriers of ESβL- and AmpC-positiveE. coli to the medical setting increases the possibility of other patients acquiring infection in the same hospital. Our results emphasize the necessity for continuous surveillance in hospitals to detect the ESβL-, AmpC enzyme-, and carbapenemase-producing strains and multidrug strains as well applying effective strategies for antimicrobial therapy and infection control measures to decrease the abuse and misuse of antimicrobial agents against resistant strains and to prevent their spread.



---

*Source: 3704150-2016-05-31.xml*